This page is part of the Safetots Crisis SOPs, a framework for prevention and treatment of the most relevant crisis situations in pediatric anaesthesia.
← previous (Local anaesthetic systemic toxicity – LAST) | next (Can´t Oxygenate – Can´t Ventilate) →
Summary
Malignant hyperthermia crisis occurs in response to volatile anesthetic agents and depolarizing muscle relaxants (suxamethonium). Prevention and immediate treatment with dantrolene is life-saving.
Background
- malignant hyperthermia is a life-threatening metabolic response to volatile anesthetic agents or succinylcholine (suxamethonium). Previous uneventful exposure to these agents does not guarantee safe use
- mortality may approach 70% if untreated, with dantrolene treatment mortality approximates 3-5%
Prevention
- recognition of patients at risk through careful medical and family history and/ or consultation with specialist Malignant Hyperthermia reference center
- do not use volatiles or succinylcholine (suxamethonium) in patients at risk
- reduce preoperative anxiety
- use a vapor free anesthetic machine if possible, if not available prepare machine according to manufacturer’s guidelines and use a new breathing circuit, rebreathing bag, and gas sampling tubes
- consider vapor scavenging filters
- ensure dantrolene availability
Treatment
Call for help early, initiate action plan and allocate specific tasks:
- stop potential trigger agents immediately and give 100% oxygen
- consider installing clean breathing system, remove inhalational agents and increase fresh gas flow to maximum, consider vapor scavenging filters
- hyperventilate to achieve normocapnia
- maintain anesthesia using non-volatile anesthetics and opioids as well as non-depolarizing muscle relaxants, curtail surgery if possible
- give dantrolene (2.5mg/kg every 5 minutes until effect – max. 20mg/kg): need to assign one person to correctly reconstitute dantrolene from powder formulation
- active cooling
- treat or prevent hyperkalemia, acidosis, arrhythmias (no calcium channel antagonists) and prevent acute renal failure and coagulopathy
- continuous monitoring of vital signs including peripheral and core temperature, invasive monitoring for repeated blood sampling
- check plasma CK
Post Care
- continue monitoring postoperatively on PICU, repeat dantrolene as required
- repeat plasma CK
- monitor and prevent acute renal failure and compartment syndrome
- counsel patient and family members
- arrange referral to Malignant Hyperthermia Unit
References
- Salazar JH, Yang J, Shen L, Abdullah F, Kim TW. Pediatric malignant hyperthermia: risk factors, morbidity, and mortality identified from the Nationwide Inpatient Sample and Kids’ Inpatient Database. Paediatr Anaesth. 2014; 24: 1212-6.
- Litman RS, Griggs SM, Dowling JJ, Riazi S. Malignant Hyperthermia Susceptibility and Related Diseases. Anesthesiology. 2018; 128: 159-67.
- Cummings T, Der T, Karsli C. Repeated non-anesthetic malignant hyperthermia reactions in a child. Paediatr Anaesth. 2016; 26: 1202-3.
- Shapiro F, Athiraman U, Clendenin DJ, Hoagland M, Sethna NF. Anesthetic management of 877 pediatric patients undergoing muscle biopsy for neuromuscular disorders: a 20-year review. Paediatr Anaesth. 2016; 26: 710-21.
- Wappler F. S1-Leitlinie maligne Hyperthermie. Der Anaesthesist 2018; 67: 529–32.
- AAGBI. Malignant Hyperthermia Crisis. AAGBI Safety Guideline. https://www.aagbi.org/publications/publications-guidelines/M/R
- Hopkins PM, Rüffert H, Snoeck MM, Girard T, Glahn KP, Ellis FR, Müller CR, Urwyler A; European Malignant Hyperthermia Group. European Malignant Hyperthermia Group guidelines for investigation of malignant hyperthermia susceptibility. Br J Anaesth 2015; 115: 531-9.
See all Cs:
- Can´t Oxygenate – Can´t Ventilate
- Can´t Intubate
- Can Intubate – Can’t Oxygenate
- Can´t Cannulate – Failed Venous Access
- Anaphylaxis
- Major Hemorrhage
- Perioperative Pulmonary Aspiration
- Tonsillar Bleeding
- Local Anesthetic Systemic Toxicity – LAST
- Malignant Hyperthermia Crisis – MH
Learn about …
- Rights of the child (10Rs)
- Personal and institutional competence (5Ws)
- Quality and equilibrium (10Ns)
- Crisis situations (10Cs)
- Research
- Quality Improvement
- Parental discussion
Explore …
- Safetots Education
- Information for parents
- Safetots mission and story
- Safetots network and members
- Safetots publications
- Safetots sponsors
- Safetots supporting organisations